Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients

Overview of attention for article published in Diagnostic Pathology, February 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#9 of 1,184)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 6 news stories from 6 outlets.

The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test displayed the capability to stratify patients with cutaneous…

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the…

FRIENDSWOOD, Texas--(Business Wire)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment…

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.